

(56)

References Cited

OTHER PUBLICATIONS

- Santos et al., "The Nicotinic Allosteric Potentiating Ligand Galantamine Facilitates Synaptic Transmission in the Mammalian Central Nervous System," *Mol. Pharmacol.*, vol. 61: pp. 1222-1234 (2002).
- Shabunova et al., "Effect of cholinesterase inhibitors on the electrical excitability of the membrane of frog muscle fiber," *Fiziol Zh SSSR Im I M Sechenova*, vol. 68:9 pp. 1223-1228 (1982) (Abstract).
- International Search Report and Written Opinion dated Dec. 28, 2006 for International PCT Application No. PCT/US05/33789, National Stage entry of parent U.S. Appl. No. 11/575,945.
- European Office Action dated Apr. 21, 2011 for European Patent Application No. 05 812 994.1, corresponding to parent Appl. No. 11/575,945.
- Kugusheva, L. I. et al., Interaction of Membrane-Bound and Solubilized Acetylcholinesterase of Human 4 and Bovine Erythrocytes with Organophosphorus Inhibitors, *journal*, 1986, vol. 58 No. 3, pp. 13-18, *Ukrainskii Biokhimitskii Zhurnal*, Russia.
- Muggleton et al., Assessment of a Combination of Physostigmine and Scopolamine as Pretreatment Against the Behavioural Effects of Organophosphates in the Common Marmoset, *journal*, 2003, vol. 166 No. 3, pp. 212-220, *Psychopharmacology*, Springer-Verlag, Germany.
- Storch et al., Physostigmine, galanthamine and codeine act as 'non-competitive nicotinic receptor agonists', on clonal rat pheochromocytoma cells, *journal*, 1995, vol. 290 No. 3, pp. 207-219, *European Journal of Pharmacology*, Elsevier Science B.V., Netherlands.
- Tonkopi et al., Study of Characteristics of the Interaction of Galanthamine with AcetylcholinEsterase of the Mouse Brain in In-Vivo Experiments, 1976, vol. 82 No. 7, pp. 823-825.
- Tonkopi V. D., Oxidative stress in the mechanism of organophosphates neurotoxicity, 2003, vol. 144 No. Suppl. 1, pp. 132.
- Australian Office Action for AU Application No. 2005289808, May 27, 2010, corresponding to parent U.S. Appl. No. 11/575,945.
- Israeli Office Action for Application No. 182048, Jun. 23, 2011, corresponding to US parent U.S. Appl. No. 11/575,945.
- Kenneth J. Keller, Overcoming Inhibitions, *PNAS* Sep. 5, 2006; vol. 103 No. 36; pp. 13263-13264.
- Albuquerque et al., Effective countermeasure against poisoning by organophosphorous insecticides and nerve agents, *PNAS* Aug. 29, 2006; vol. 103 No. 35; pp. 13220-13225.
- Bajgar JIR1: Organophosphates/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis, and treatment', *Advances in Clinical Chemistry*, Academic Press, London, GB, vol. 38. Jan. 1, 2004, pp. 151-216, XPO091 09278, ISSN: 0065-2423. DOI: 10.1016/S0065-2423(04)38006-6.
- Lopes et al.: "Competitive Antagonism between the Nicotinic Allosteric Potentiating Ligand Galantamine and Kynurenic Acid at $\alpha 7^*$ Nicotinic Receptors", *Journal of Pharmacology and Experimental Therapeutist*, Published online before print Apr. 19, 2007, doi: 10.1124/jpet.107.123109 JPET Jul. 2007 vol. 322 No. 1 48-58.
- Ludwig et al.: "Localization by site-directed mutagenesis of a galantamine binding site on a7 nicotinic acetylcholine receptor extracellular domain", *Journal of Receptors and Signal Transduction*, 2010; 30(6): 469-483.
- Mamczarz et al.: "Galantamine counteracts development of learning impairment in guinea pigs exposed to the organophosphorus poison soman: Clinical significance", *NeuroToxicology* 32 (2011), pp. 785-798.
- Pereira et al., "Unconventional Ligands and Modulators of Nicotinic Receptors", *Wiley Periodicals Inc.* 2002, pp. 479-500.
- Samochocki et al: "Galantamine is an allosterically potentiating ligand of the human $\alpha 4/\beta 2$ nAChR", *ACTA Neurologica Scandinavica* 2000: Supplement 176: pp. 68-73.
- Bajgar: *J.Med. Chem. Def.*, Feb. 2004, vol. 1, pp. 1-16.

* cited by examiner